Publications

467 publications

Enter search criteria
Fill in keyword(s) to narrow your search.
Period
You can select a specific type of a publication you are looking for, such as press releases or speeches
Sort by:
  1. Transcatheter aortic valve implantation

    Transcatheter aortic valve implantation (TAVI) does not fulfil the established medical science and medical practice criterion for ...

    Report | 26-10-2012

  2. Prednisone (Lodotra) for the indication ‘active rheumatoid arthritis’

    The therapeutic value of MR prednisone is equal to that of IR prednisone for the treatment of adult patients with moderate to ...

    Report | 26-10-2012

  3. Multifocal and accommodating lenses in combination with cataract operations

    Multifocal lenses do have mild adverse events, but these are not regarded as deciding factors. A well-informed patient can weigh ...

    Report | 26-10-2012

  4. Pravastatin/fenofibrate (Pravafenix) for the indication ‘dyslipidaemia with high-concentration triglycerides’

    The use of pravastatin/fenofibrate to treat adult patients with an increased risk of coronorary heart disease and who suffer from ...

    Report | 22-10-2012

  5. Pasireotide (Signifor) for the indication ‘Cushing’s Disease’

    The results of these studies indicate only that these drugs are effective and safe in patients from whom surgery is not an option ...

    Report | 24-09-2012

  6. Vandetanib (Caprelsa) for the indication ‘metastatic medullary thyroid cancer’

    Vandetanib has a therapeutic added value in comparison with placebo for the treatment of aggressive and symptomatic medullary ...

    Report | 24-09-2012

  7. Tegafur/gimeracil/oteracil (Teysuno) for the indication ‘advanced gastric cancer’.

    The standard treatment triplet has been proven to have a significant survival advantage in comparison with a doublet without ...

    Report | 24-09-2012

  8. Eribulin (Halaven) for the indication ‘patients with locally advanced or metastatic breast cancer’.

    The therapeutic added value of eribulin is equal to that of TPC. Based on this comparison, however, it is impossible to say ...

    Report | 27-08-2012

  9. Albumin-bound paclitaxal (Abraxane) for the indication ‘metastatic breast cancer’

    The conclusion is that the therapeutic value of NAB-paclitaxel is comparable to that of SB-paclitaxel in the second-line or ...

    Report | 27-08-2012

  10. Endovascular treatment of complex aneurysms of the aorta

    This assessment shows that there is insufficient evidence of high methodological quality to be able to conclude that the ...

    Report | 10-08-2012